Abstract
Short sequence amino acids or oligopeptides have recently garnered attention for use as treatments for a myriad of dermatologic disorders due to their ability to effect and modulate various biological processes in the epidermis and dermis, rendering them promising candidates as medical and cosmeceutical therapeutics. Major advantages include their relative ease of synthesis and multitude of modifications that can be applied to enhance potency, affinity, specificity, hydrophilicity or hydrophobicity and cytotoxicity. Given the photoprotective effects of eumelanin on skin, there has been substantial interest in developing agents, particularly α-MSH analogs, that can induce ‘sunless tanning’ helping reduce risk of melanoma and non-melanoma skin cancer. In this mini review, we present some of the recent and leading peptide modulators of melanogenesis with relevant clinical data and medical indications. Short sequence oligopeptides with tyrosinase inhibitory activity that can significantly reduce hyperpigmentation, as well α-MSH analogs that can enhance eumelanogenesis, are currently being clinically tested for treatment of erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, actinic keratosis, and “sunless tanning”. Success in developing such products can help reduce the incidence of skin cancer, one that surpasses that of all other human cancers combined.
Keywords: α-MSH analogs, hyperpigmentation, hypopigmentation, melanocortin 1 receptor, melanogenesis, tyrosinase.
Current Topics in Medicinal Chemistry
Title:Minireview: Peptide Analogs and Short Sequence Oligopeptides as Modulators of Skin Pigmentation
Volume: 14 Issue: 12
Author(s): Anan Abu Ubeid and Basil M. Hantash
Affiliation:
Keywords: α-MSH analogs, hyperpigmentation, hypopigmentation, melanocortin 1 receptor, melanogenesis, tyrosinase.
Abstract: Short sequence amino acids or oligopeptides have recently garnered attention for use as treatments for a myriad of dermatologic disorders due to their ability to effect and modulate various biological processes in the epidermis and dermis, rendering them promising candidates as medical and cosmeceutical therapeutics. Major advantages include their relative ease of synthesis and multitude of modifications that can be applied to enhance potency, affinity, specificity, hydrophilicity or hydrophobicity and cytotoxicity. Given the photoprotective effects of eumelanin on skin, there has been substantial interest in developing agents, particularly α-MSH analogs, that can induce ‘sunless tanning’ helping reduce risk of melanoma and non-melanoma skin cancer. In this mini review, we present some of the recent and leading peptide modulators of melanogenesis with relevant clinical data and medical indications. Short sequence oligopeptides with tyrosinase inhibitory activity that can significantly reduce hyperpigmentation, as well α-MSH analogs that can enhance eumelanogenesis, are currently being clinically tested for treatment of erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, actinic keratosis, and “sunless tanning”. Success in developing such products can help reduce the incidence of skin cancer, one that surpasses that of all other human cancers combined.
Export Options
About this article
Cite this article as:
Ubeid Abu Anan and Hantash M. Basil, Minireview: Peptide Analogs and Short Sequence Oligopeptides as Modulators of Skin Pigmentation, Current Topics in Medicinal Chemistry 2014; 14 (12) . https://dx.doi.org/10.2174/1568026614666140601221519
DOI https://dx.doi.org/10.2174/1568026614666140601221519 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Nanoparticles: Properties and Applications in Cancer Immunotherapy
Current Pharmaceutical Design Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry Smart Electrospun Nanofibers for Controlled Drug Release: Recent Advances and New Perspectives
Current Pharmaceutical Design Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience Development and Comparison of Nanosponge and Niosome based Gel for the Topical Delivery of Tazarotene
Pharmaceutical Nanotechnology Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Bioactivity of Hybrid Polymeric Magnetic Nanoparticles and Their Applications in Drug Delivery
Current Pharmaceutical Design Selective Matrix Metalloproteinase Inhibitors for Cancer
Current Medicinal Chemistry Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry